Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial was written by Kwak, Nakwon;Jeon, Doosoo;Park, Youngmok;Kang, Young Ae;Kim, Kyung Jong;Kim, Young Ran;Kwon, Byoung Soo;Kwon, Yong-Soo;Kim, Hyung-Jun;Lee, Jae Ho;Lee, Ji Yeon;Lee, Jung-Kyu;Mok, Jeongha;Cheon, Minkyoung;Park, Jiwon;Hahn, Seokyung;Yim, Jae-Joon. And the article was included in Trials in 2022.SDS of cas: 13292-46-1 This article mentions the following:
The standard treatment regimen for drug-sensitive tuberculosis (TB), comprising four companion drugs, requires a min. duration of 6 mo, and this lengthy treatment leads to poor adherence and increased toxicity. To improve rates of adherence, reduce adverse events, and lower costs, a simplified and shortened treatment regimen is warranted. This study is a multicenter, open-label randomized clin. trial of non-inferiority design that compares a new regimen with the conventional regimen for drug-sensitive pulmonary TB. The investigational group will use a regimen of high-dose rifampicin (30 mg/kg/day) with isoniazid and pyrazinamide, and the treatment will be maintained for 12 wk after the achievement of neg. conversion of sputum culture. The control group will be treated for 6 mo with a World Health Organization-endorsed regimen consisting of isoniazid, rifampicin (10 mg/kg/day), ethambutol, and pyrazinamide. The primary endpoint is the proportion of unfavorable outcomes at 18 mo after randomization. Secondary outcomes include time to unfavorable treatment outcome, time to culture conversion on liquid medium, treatment success rate at the end of treatment, proportion of recurrence at 18 mo after randomization, time to recurrence after treatment completion, and adverse events of grade 3 or higher during the treatment. We predict a 10% unfavorable outcome for the control group, and 0% difference from the investigational group. Based on 80% verification power and a 2.5% one-sided significance level for a non-inferiority margin of 6%, 393 participants per group are required. Considering the 15% dropout rate, a total of 926 participants (463 in each group) will be recruited. This study will inform on the feasibility of the treatment regimen using high-dose rifampicin with a shortened and individualized treatment duration for pulmonary TB. Trial registration: ClinicalTrials.gov NCT04485156. In the experiment, the researchers used many compounds, for example, 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1SDS of cas: 13292-46-1).
8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1) belongs to piperazine derivatives. Piperazine belongs to the family of medicines called anthelmintics. Intermediate for a wide range of pharmaceuticals, polymers, dyes, corrosion inhibitors, rubber accelerators and surfactants.SDS of cas: 13292-46-1
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics